1. Home
  2. ORKA vs EEX Comparison

ORKA vs EEX Comparison

Compare ORKA & EEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORKA
  • EEX
  • Stock Information
  • Founded
  • ORKA 2004
  • EEX 2013
  • Country
  • ORKA United States
  • EEX United States
  • Employees
  • ORKA N/A
  • EEX N/A
  • Industry
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • EEX Advertising
  • Sector
  • ORKA Health Care
  • EEX Consumer Discretionary
  • Exchange
  • ORKA Nasdaq
  • EEX Nasdaq
  • Market Cap
  • ORKA 354.2M
  • EEX 910.8M
  • IPO Year
  • ORKA N/A
  • EEX 2017
  • Fundamental
  • Price
  • ORKA $12.60
  • EEX $5.44
  • Analyst Decision
  • ORKA Strong Buy
  • EEX Strong Buy
  • Analyst Count
  • ORKA 8
  • EEX 2
  • Target Price
  • ORKA $39.71
  • EEX $7.90
  • AVG Volume (30 Days)
  • ORKA 341.3K
  • EEX 105.7K
  • Earning Date
  • ORKA 08-15-2025
  • EEX 08-06-2025
  • Dividend Yield
  • ORKA N/A
  • EEX 1.13%
  • EPS Growth
  • ORKA N/A
  • EEX N/A
  • EPS
  • ORKA N/A
  • EEX 0.02
  • Revenue
  • ORKA N/A
  • EEX $413,100,000.00
  • Revenue This Year
  • ORKA N/A
  • EEX $14.85
  • Revenue Next Year
  • ORKA N/A
  • EEX $6.42
  • P/E Ratio
  • ORKA N/A
  • EEX $215.37
  • Revenue Growth
  • ORKA N/A
  • EEX 4.87
  • 52 Week Low
  • ORKA $5.49
  • EEX $3.22
  • 52 Week High
  • ORKA $52.32
  • EEX $6.65
  • Technical
  • Relative Strength Index (RSI)
  • ORKA N/A
  • EEX 73.43
  • Support Level
  • ORKA N/A
  • EEX $4.80
  • Resistance Level
  • ORKA N/A
  • EEX $5.00
  • Average True Range (ATR)
  • ORKA 0.00
  • EEX 0.14
  • MACD
  • ORKA 0.00
  • EEX 0.02
  • Stochastic Oscillator
  • ORKA 0.00
  • EEX 100.00

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

Share on Social Networks: